Triamcinolone acetonide (TA) is a long-acting and relatively insoluble corticosteroid with reported efficacy when injected by intravitreal or subtenon methods as an adjunctive treatment for inflammatory, proliferative, neovascular, or edematous eye diseases [1-8]. Since TA has been shown to suppress unwanted intraocular proliferation of cells, reduce inflammation, stabilize the blood-ocular barrier, and downregulate the production of vascular endothelial growth factor [9-13], TA was thought to be a potentially useful additional tool in the treatment of proliferative diabetic retinopathy (PDR). Actually, some studies have demonstrated that intravitreal TA injection as an adjunctive procedure in pars plana vitrectomy for PDR reduces postoperative intraocular inflammation and is effective in the prevention of recurrent vitreous hemorrhage [7,14].

Intraocular gases in vitreoretinal surgery are widely used. In conjunction with advanced surgical techniques, intraocular gases have improved the ability to successfully treat retinal detachments that have been made more complicated by proliferative vitreoretinopathy (PVR), giant
tears, and posterior tears.

Thompson et al. [15] used sulfur hexafluoride (SF₆) for tamponade of suspected retinal breaks or to prevent postoperative vitreous hemorrhage. Yang et al. [16] evaluated the hemostatic effect of intravitreal injection of perfluoropropane (C₃F₈, 10%) and concluded that it may reduce the rate of recurrent vitreous hemorrhage. Farahai et al. [17] also revealed that SF₈ (20%) in the vitreous cavity provides temporary tamponade and reduces the incidence of postoperative diabetic vitreous hemorrhage.

However, on review of the literature, no clinical studies were found on the use of posterior subtenon TA in gas-filled eyes with PDR. When localized steroid therapy is needed to reduce postoperative intraocular inflammation, intravitreal triamcinolone acetonide (IVTA) has been shown to be effective. IVTA is more invasive and also has a risk for intraocular pressure (IOP) elevation. Therefore, we thought that a posterior subtenon triamcinolone injection of TA could be used safely to lower the inflammatory reaction with less risk of IOP elevation. We wanted to obtain both a faster recovery time and maintain a normal IOP after vitrectomy. Therefore, we investigated the clinical outcome of patients who received a subtenon TA injection in gas-filled eyes after vitreoretinal surgery for complicated PDR.

**Materials and Methods**

Twenty-seven eyes of 27 patients who underwent pars plana vitrectomy for treatment of PDR with tractional or combined tractional-rhegmatogenous retinal detachment, with/without vitreous hemorrhage, were included in this study. Exclusion criteria were patients with previous ocular surgery, history of any ocular disease or trauma, intravitreal silicone oil injection during surgery, previous intravitreal bevacizumab or TA injection, and previous posterior subtenon injection of TA. Patients who did not receive gas injection during surgery were also excluded. If there was a failure to execute the injection properly, the triamcinolone acetonide was regurgitated, and the case was excluded. Informed consent was obtained from all patients after a full explanation of the potential effects of a subtenon TA injection.

Surgery was carried out under general or retrobulbar anesthesia. The standardized technique of pars plana vitrectomy was performed using three 20-gauze pars plana sclerotomies. The vitreous was removed up to the vitreous base and the posterior vitreous surface. Phakic eyes underwent lens extraction and IOL implantation. Depending on the clinical situation, additional procedures were performed, such as peeling, delamination, and segmentation of membranes, temporary application of perfluorocarbon liquids, and relaxing retinotomies. Then, panretinal endolaser photocoagulation including periphery was performed. Before closing the sclerotomy sites, C₃F₈ (15%) was used as a tamponade in all eyes. After closing the sclerotomy sites at the end of the operation, 40 mg of TA was injected into 27 eyes in the study group. The TA was slowly injected through the conjunctiva and tenon’s capsule and applied to the bare sclera near the superotemporal fornix using a curved cannula. After the application was complete, gentle pressure was maintained by a sterile swab along the path of the cannula to avoid TA reflux. All the patients were operated on by the same retinal surgeon (YHP). All patients were examined by the operator during the 6 months follow-up period. At each visit, best-corrected visual acuity, IOP, intraocular inflammation, retinal redetachment rate, PVR, postoperative vitreous hemorrhage, macular pucker formation, and the need for further vitreoretinal reoperation were measured. Snellen visual acuities measured at each visit were converted to the logarithm of the minimum angle of resolution (logMAR) scale for statistical analysis. Intraocular inflammation in the anterior chamber was graded on a scale of 0 to 4; where 0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe. The extent of vitreous re-bleeding was graded according to the following scales: 0 = no vitreous hemorrhage, 1 = mild vitreous hemorrhage with visible fundus details, 2 = moderate vitreous hemorrhage with no visible fundus details but with an orange fundus reflex, 3 = severe vitreous hemorrhage with no fundus details and no fundus reflex. PVR was graded according to four grades (A, B, C, and D), suggested by the Retina Society Terminology Committee [18].

The study group was compared with a control group consisting of 29 eyes (29 patients) with complicated PDR with tractional or combined tractional-rhegmatogenous retinal detachment, with/without vitreous hemorrhage. The patients of the control group, which was formed retrospectively, were matched with those of the study group for age, sex, duration and type of diabetes, prevalence of hypertension, lens status, previous treatment of laser photocoagulation, preoperative refractive error, and preoperative IOP (Table 1). Patients in the control group also underwent pars plana vitrectomy and C₃F₈ gas tamponade in a similar way as the patients in the study group. The operations were performed by the same surgeon who used the same technique and instruments. However, the patients in the control group did not receive a subtenon injection of TA at the end of the surgery.

**Results**

Clinical characteristics and demographics of the both groups are described in Table 1. Follow-up period in the both groups was 6 months. The two groups were comparable in terms of demographics and preoperative factors (Table 1). Single-operation retinal reattachment was achieved in 25 eyes (92.6%) 6 months after surgery in the study
group and in 26 eyes (89.7%) in the control group. Retinal redetachment occurred in 2 eyes (7.4%) in the study group and in 3 eyes (10.3%) in the control group over the course of 6 months. The differences between the two groups were not significant ($p = 1.000$). Postoperative PVR developed in 4 eyes (14.8%) (3 eyes with grade B, and 1 eye with grade C) in the study group and 7 eyes (24.1%) (4 eyes with grade B, and 3 eyes with grade C) in the control group. There was no statistically significant difference in PVR development between the two groups ($p = 0.506$). Macular pucker developed in 1 eye (3.7%) in the study group and 3 eyes (10.3%) in the control group. Two eyes (7.4%) in the study group required reoperation for retinal redetachments, and 4 eyes (13.8%) in the control group required reoperation for retinal redetachments (3 eyes). In the control group, one eye developed a significant macular pucker. The frequencies of reoperation and macular pucker formation did not differ significantly between the two groups ($p = 0.506$, $p = 0.671$, $p = 0.612$). Although the differences in postoperative PVR development, reoperation, and macular pucker formation between two groups were not statistically significant, the frequencies of those were lower in the study group than in the control group.

LogMAR visual acuity determined at 6 months after the operation was 0.49 ± 0.47 in the study group and 0.54 ± 0.42 in the control group. There was no significant difference between the two groups ($p = 1.000$). Significant improvement in visual acuity was observed in both groups. However, the differences between the two groups were not significant ($p = 0.793$). The mean improvement of visual acuity was $1.43 \pm 0.73$ logMAR units in the study group and $1.34 \pm 0.69$ logMAR units in the control group (Table 2). There was no statistically significant difference in IOP between the two groups at any point of the follow-up period ($p > 0.05$) (Table 2). Two eyes in the study group and two eyes in the control group had a temporary IOP rise in excess of 21 mmHg. In the both groups, there were no significant difference in intraocular inflammation since the first postoperative day ($p > 0.05$) (Table 2). Vitreous hemorrhage after the pars plana vitrectomy occurred in 2 eyes (7.4%, 2 eyes in grade 1) in the study group and in 3 eyes (10.3%, 3 eyes in grade 1) in the control group. There was no significant difference in the rate of postoperative vitreous hemorrhage between the two groups ($p = 1.000$). Iris neovascularization was absent in the study group, but developed in 1 eye (3.4%) in the control group during the 6 months follow-up period. There was no significant difference in the rate of iris neovascularization between the two groups ($p = 1.000$). No cases of endophthalmitis or neovascular glaucoma occurred postoperatively in both groups.

### Discussion

The effect of subtenon TA as an adjunctive treatment in gas-filled eyes in patients with complicated PDR was evaluated in this non-randomized comparative study. Although TA has been used as an intravitreal adjunctive treatment for PDR and retinal detachment with PVR [7,19-21], and as posterior subtenon injection for visual loss caused by retinal edema and other reversible inflammatory diseases

### Table 1. Demographics and clinical characteristics of patients who underwent vitrectomy and gas tamponade with/without subtenon injection of TA for complicated proliferative diabetic retinopathy

| Variable                  | With subtenon TA (study group) | Without subtenon TA (control group) | $p$-value |
|---------------------------|--------------------------------|-------------------------------------|----------|
| No. of eyes               | 27                             | 29                                  | 0.765    |
| Age (yr)                  | 54.9 ± 9.1                     | 55.9 ± 11.2                         |          |
| Right eye / left eye      | 15 / 12                        | 15 / 14                             | 0.795    |
| Sex (female / male)       | 16 / 11                        | 12 / 17                             | 0.285    |
| Duration of diabetes      | 15.3 ± 8.9                     | 14.8 ± 7.3                          | 0.326    |
| Type of diabetes          |                                |                                     |          |
| Type 1                    | 2                              | 3                                   |          |
| Type 2                    | 25                             | 26                                  | 1.000    |
| Hypertension              | 13                             | 12                                  | 0.788    |
| Lens status               |                                |                                     |          |
| Phakic                    | 26                             | 28                                  |          |
| Pseudophakic              | 1                              | 0                                   |          |
| Aphakic                   | 0                              | 1                                   | 0.736    |
| Previous PRP             | 22                             | 23                                  | 1.000    |
| Refractive error          | 0.23 ± 1.92                    | 0.02 ± 1.96                         | 0.352    |
| Preoperative visual acuity (logMAR) | 1.92 ± 0.41 | 1.88 ± 0.54 | 0.634    |
| Preoperative IOP (mmHg)   | 14.7 ± 6.1                     | 16.1 ± 4.2                          | 0.231    |

TA = triamcinolone acetonide; PRP = panretinal photocoagulation; logMAR = logarithm of minimal angle of resolution; IOP = intraocular pressure.
there have been no studies to our knowledge to investigate the clinical results of a subtenon TA injection in gas-filled eyes. Regarding intravitreal TA as an adjunctive treatment for PDR, there were conflicting results. Faghihi et al. [14] reported patients with intravitreal TA injection at the end of vitrectomy had better visual acuity outcomes, lower re-bleeding, and reoperation rates compared with other patients that didn’t receive intravitreal TA. Conversely, Jonas et al. [24] reported intravitreal TA appeared not to be helpful when used as an adjunctive treatment.

In the present study, the eyes of the study group receiving the subtenon TA injection and the eyes of the control group without the subtenon TA injection did not differ significantly in the rate of postoperative PVR development, retinal redetachments, macular pucker formation, reoperation, and postoperative vitreous hemorrhage. In agreement with these findings, the mean improvement of visual acuity through the entire follow-up period and the visual acuities at the end of the study did not differ between the two groups. Regarding the present study, one may infer that the subtenon TA used as an adjunct in gas-filled eyes did not have a significant anti-proliferative property and did not improve the final visual results.

Steroids injected into the globe stabilize the blood-retinal barrier and inhibit the secretion of vascular endothelial growth factor, which could decrease the vascular permeability and result in the prevention of macular edema and increase of visual acuity [4,25-30]. It may also inhibit the stimulation and migration of retinal endothelial cells, reduce the rate of fibrous proliferation and tractional retinal

| Variable                              | With subtenon TA (study group, n = 27) | Without subtenon TA (control group, n = 29) | p-value |
|---------------------------------------|---------------------------------------|---------------------------------------------|---------|
| Postoperative visual acuity (logMAR) |                                       |                                             |         |
| Preop                                 | 1.92 ± 0.41                           | 1.88 ± 0.54                                 | 0.634   |
| Postop 6 months                       | 0.49 ± 0.47                           | 0.54 ± 0.42                                 | 0.154   |
| Improvement                           | 1.43 ± 0.73                           | 1.34 ± 0.69                                 | 0.793   |
| Postoperative IOP (mmHg)              |                                       |                                             |         |
| POD 1                                 | 15.3 ± 4.8                            | 14.5 ± 5.0                                  | 0.894   |
| POW 1                                 | 16.6 ± 5.6                            | 16.7 ± 5.2                                  | 0.832   |
| POM 1                                 | 16.2 ± 4.3                            | 16.1 ± 4.3                                  | 0.436   |
| POM 2                                 | 16.3 ± 4.8                            | 16.1 ± 3.9                                  | 0.897   |
| POM 3                                 | 17.4 ± 4.3                            | 16.9 ± 4.2                                  | 0.756   |
| POM 6                                 | 16.1 ± 5.3                            | 15.5 ± 4.5                                  | 0.343   |
| Intraocular inflammation in AC        |                                       |                                             |         |
| POD 1                                 | 1.6 ± 0.9                             | 1.8 ± 1.1                                   | 0.181   |
| POW 1                                 | 0.5 ± 0.5                             | 0.7 ± 0.7                                   | 0.335   |
| POM 1                                 | 0.2 ± 0.4                             | 0.2 ± 0.3                                   | 0.837   |
| Retina attached at 6 months (%)       | 25 (92.6)                             | 26 (89.7)                                   | 1.000   |
| Retinal redetachment (%)              | 2 (7.4)                               | 3 (10.3)                                    | 1.000   |
| PVR (%)                               | 4 (14.8)                              | 7 (24.1)                                    | 0.506   |
| Grade A                               | 0                                     | 0                                            |         |
| Grade B                               | 3                                     | 4                                            |         |
| Grade C                               | 1                                     | 3                                            |         |
| Grade D                               | 0                                     | 0                                            |         |
| Macular pucker formation (%)          | 1 (3.7)                               | 3 (10.3)                                    | 0.612   |
| Reoperation (%)                       | 2 (7.4)                               | 4 (13.8)                                    | 0.671   |
| For retinal redetachment              | 2                                     | 3                                            |         |
| For macular pucker                    | 0                                     | 1                                            |         |
| Vitreous hemorrhage after surgery (%) | 2 (7.4)                               | 3 (10.3)                                    | 1.000   |
| Grade 1                               | 2                                     | 3                                            |         |
| Grade 2                               | 0                                     | 0                                            |         |
| Grade 3                               | 0                                     | 0                                            |         |
| Iris neovascularization               | 0                                     | 1                                            | 1.000   |
| Neovascular glaucoma                  | 0                                     | 0                                            |         |
| Endophthalmitis                       | 0                                     | 0                                            |         |

TA = triamcinolone acetonide; logMAR = logarithm of minimal angle of resolution; IOP = intraocular pressure; POD = postoperative day; POW = postoperative week; POM = postoperative month; AC = anterior chamber; PVR = proliferative vitreoretinopathy.
detachment, and suppress the angiogenesis by decreasing many inflammatory cytokines secretions [30-32]. All of these effects could help to reduce the various complications related to proliferative diabetic retinopathy and to decrease the reoperation rate. However, our clinical results in gas-filled eyes indicated that subtenon TA injection did not seem to have any beneficial effects in anti-proliferative outcomes and visual acuity. The results in this study may be caused by several reasons. First, TA itself as an adjunctive treatment is not associated with better clinical outcomes. Secondly, a single injection of TA is not enough to produce better clinical results. Lastly, the adjunctive effects of TA through the trans-scleral route are not significant. As far as we know, several studies have shown that a subtenon injection of TA is effective for treating choroidal inflammatory diseases [23,33].

Shen et al. [34] have studied the pharmacokinetics of triamcinolone acetonide after a single 40 mg posterior subtenon application. In their study, a posterior subtenon TA injection can provide a high local TA level (8,632 ng/day/mL for aqueous, 1,262 ng/day/mL for vitreous) in ocular tissues but yields a low level of TA in systemic circulation (17.4 ng/day/mL for plasma). TA entered the aqueous more rapidly than it entered the vitreous, which had an obvious absorption phase during the first 24 hours.

In either case, the injection of subtenon TA did not seem to be helpful when used as an adjunctive tool in a gas-filled eye. Although the study population and its design were different from the present study, Entezari et al. [35] insisted that the subtenon route failed to show a significant effect because of inadequate penetration through sclera, mentioning posterior subtenon TA injection had no therapeutic effects on refractory diabetic macular edema.

One of the major concerns after intravitreal TA injection is an increased IOP. An elevation of IOP has been reported in many eyes undergoing intravitreal injection of TA for management of various ocular diseases [36-40]. However, the elevation of IOP is not a major problem in eyes receiving a subtenon injection of TA [41]. This agrees with our study in which the number of eyes experiencing IOP elevation in excess of 21 mmHg was just two in each group, and the pressure rise in the two eyes in the study group returned to a normotensive level on subsequent examination without any antiglaucomatous therapy. However, it was not certain whether the IOP elevation was caused by the subtenon TA injection.

Although this study provided for consistent surgical technique from one retinal surgeon and the same instruments to reduce the influence of external factors, there were certain limitations. First, the number of patients and the follow-up period were limited. A larger number of eyes might have proved the beneficial effect of subtenon TA in gas-filled eyes, and a longer period of follow-up may have resulted in different clinical results to some extent. Secondly, the extremes of disease severity were not stratified. Finally, the study was not a randomized prospective investigation.

In conclusion, the results of the present study suggest that the outcomes of vitrectomy in complicated proliferative diabetic retinopathy have not been improved by subtenon TA injection in gas-filled eyes. Despite the theoretical advantages of the anti-inflammatory and anti-angiogenic effects of TA, TA used as a subtenon adjunct in gas-filled eye is not strongly suggested for the treatment of complicated PDR until more large scale studies prove a therapeutic benefit of TA. In the future, we are planning to compare the effect of a TA injection in a randomized circumstance to make sure of TA’s effectiveness.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

References

1. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. *Ophthalmology* 2002;109:920-7.
2. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. *Ophthalmology* 2001;108:765-72.
3. Greenberg PB, Martidis A, Rogers AH, et al. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. *Br J Ophthalmol* 2002;86:247-8.
4. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. *Retina* 2000;20:244-50.
5. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. *Am J Ophthalmol* 2001;132:425-7.
6. Jonas JB, Sofker A. Intravitreal triamcinolone acetonide for cataract surgery with iris neovascularization. *J Refract Surg* 2002;28:2040-1.
7. Jonas JB, Hayler JK, Sofker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. *Am J Ophthalmol* 2001;131:468-71.
8. Jonas JB, Hayler JK, Sofker A, Panda-Jonas S. Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. *J Glaucoma* 2001;10:284-7.
9. Rubsamen PE, Cousins SW. Therapeutic effect of periocular corticosteroids in experimental proliferative vitreoretinopathy. *Retina* 1997;17:44-50.
10. Rubsamen PE, Davis PA, Hernandez E, et al. Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. *Arch Ophthalmol* 1994;112:407-13.
11. Berger AS, Cheng CK, Pearson PA, et al. Intravitreal sustained release corticosteroid-5-fluorouracil conjugate in the treatment of experimental proliferative vitreoretinopathy. *Invest Ophthalmol Vis Sci* 1996;37:2318-25.
12. Yang CS, Khawly JA, Hainsworth DP, et al. An intravitreal
sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol 1998;116:69-77.

13. Ando N, Sen HA, Berkowitz BA, et al. Localization and quantitation of blood-retinal barrier breakdown in experimental proliferative vitreoretinopathy. Arch Ophthalmol 1994;112:117-22.

14. Faghihi H, Taheri A, Farahvash MS, et al. Intravitreal triamcinolone acetone injection at the end of vitrectomy for diabetic vitreous hemorrhage: a randomized, clinical trial. Retina 2008;28:1241-6.

15. Thompson JT, de Bustros S, Michels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic vitreous hemorrhage. Arch Ophthalmol 1987;105:191-5.

16. Yang CM, Yeh PT, Yang CH. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology 2007;114:710-5.

17. Farrahi F, Feghhi M, Bagherzadeh B, Latifi M. Sulfur hexafluoride 20% versus lactated ringer’s solution for prevention of early postoperative vitreous hemorrhage after diabetic vitrectomy. J Ophthamlic Vis Res 2010;5:105-9.

18. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1983;90:121-5.

19. Ahmadieh H, Feghhi M, Tabatabaei H, et al. Triamcinolone acetone in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial. Ophthalmology 2008;115:1938-43.

20. Cheema RA, Peyman GA, Fang T, et al. Triamcinolone acetone as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy. Ophthalmic Surg Lasers Imaging 2007;38:365-70.

21. Munir WM, Pulido JS, Sharma MC, Buerk BM. Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. Can J Ophthalmol 2005;40:598-604.

22. Verma LK, Vivek MB, Kumar A, et al. A prospective controlled trial to evaluate the adjunctive role of posterior subtenon triamcinolone in the treatment of diffuse diabetic macular edema. J Ocul Pharmacol Ther 2004;20:277-84.

23. Helm CJ, Holland GN. The effects of posterior subtenon injection of triamcinolone acetone in patients with intermediate uveitis. Am J Ophthalmol 1995;120:55-64.

24. Jonas JB, Sofker A, Degenring R. Intravitreal triamcinolone acetone as an additional tool in pars plana vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 2003;13:468-73.

25. Sakamoto T, Miyazaki M, Hisatomi T, et al. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol 2002;240:423-9.

26. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetone for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res 2005;24:587-611.

27. Croadale CR, Brightbill FS. Subconjunctival corticosteroid injections for nonnecrotizing anterior scleritis. Arch Ophthalmol 1999;117:966-8.

28. Danis RP, Bingaman DP, Yang Y, Ladd B. Inhibition of preretal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetone. Ophthalmology 1996;103:2099-104.

29. Flomn N, Zor U. Mechanism of steroid action in ocular inflammation: inhibition of prostaglandin production. Invest Ophthalmol Vis Sci 1977;16:69-73.

30. Wilson CA, Berkowitz BA, Sato Y, et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photoagulation. Arch Ophthalmol 1992;110:1155-9.

31. Hood PP, Cotter TP, Costello JF, Sampson AP. Effect of intravenous corticosteroid on ex vivo leukotriene generation by blood leucocytes of normal and asthmatic patients. Thorax 1999;54:1075-82.

32. Ozaki NK, Beharry KD, Nishihara KC, et al. Regulation of retinal vascular endothelial growth factor and receptors in rabbits exposed to hyperoxia. Invest Ophthalmol Vis Sci 2002;43:1546-57.

33. Lafranco Dafflon M, Tran VT, Guex-Crosier Y, Herbot CP. Posterior sub-Tenon’s steroid injections for the treatment of posterior ocular inflammation: indications, efficacy and side effects. Graefes Arch Clin Exp Ophthalmol 1999;237:289-95.

34. Shen L, You Y, Sun S, et al. Intraocular and systemic pharmacokinetics of triamcinolone acetone after a single 40-mg posterior subtenon application. Ophthalmology 2010;117:2365-71.

35. Entezari M, Ahmadieh H, Dehghan MH, et al. Posterior sub-tenon triamcinolone for refractory diabetic macular edema: a randomized clinical trial. Eur J Ophthalmol 2005;15:746-50.

36. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetone and intraocular pressure. Am J Ophthalmol 2004;138:740-3.

37. Gillies MC, Kuzniarz M, Craig J, et al. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005;112:139-43.

38. Jonas JB, Degenring RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetone injection. Ophthalmology 2005;112:593-8.

39. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetone. Br J Ophthalmol 2003;87:24-7.

40. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004;122:336-40.

41. Mueller AJ, Jian G, Banker AS, et al. The effect of deep posterior subtenon injection of corticosteroids on intraocular pressure. Am J Ophthalmol 1998;125:158-63.